{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T13:37:04Z","timestamp":1794490624637,"version":"4.9.1"},"reference-count":22,"publisher":"Bentham Science Publishers Ltd.","issue":"1","funder":[{"DOI":"10.13039\/501100004410","name":"T\u00dcB\u0130TAK","doi-asserted-by":"publisher","award":["3189343"],"award-info":[{"award-number":["3189343"]}],"id":[{"id":"10.13039\/501100004410","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CRP"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>The synthesis of 225Actinium derivatives was afforded by using PSMA-\n617, DOTATATE peptides, and EDTMP ligand. Detailed experiments, quality control (QC),\nand stability studies were also well described. The radiolabelling reactions were performed in mild\nconditions with desirable radiochemical yields and high radiochemical purities.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>PSMA-617, DOTATATE were radiolabelled with 225Actinium in 0.1 M HCl in the presence\nof ascorbate buffer solution and passed through the C-18 light cartridge for purification and\nthe product was eluted by ethanol-water solution. EDTMP was also radiolabelled with 225Actinium\nwithout using any stabilizer and purification step. All products were well analyzed by R-TLC and\nR-HPLC. The stability of those compounds was also studied within the validity period of time.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>225Ac-DOTATATE and 225Ac-PSMA-617 were obtained at the same condition. The radiochemical\nyield of 225Ac-DOTATATE was less than 225Ac-PSMA 617. The stability experiments indicating\ndecay daughters of 225Actinium appeared after T0 +1 h due to the recoil effect radiolysis.\nOn the other hand, 225Ac-EDTMP was more stable than DOTA-peptide radiolabelled compounds.\n225Ac-EDTMP was produced with more than 95% radiochemical yield and 99% radiochemical purity.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>A detailed chemistry study was presented for the synthesis of 225Actinium derivatives\nin mild conditions with absolute radiochemical purities and high yields. The experimental results\nshowed that 225Ac-EDTMP could be a suitable radiopharmaceutical alternative for bone metastases\narising from primer tumors as a cocktail therapy.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1874471014666210528123936","type":"journal-article","created":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T06:16:59Z","timestamp":1622441819000},"page":"76-83","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Detailed Chemistry Studies of 225Actinium Labeled Radiopharmaceuticals"],"prefix":"10.2174","volume":"15","author":[{"given":"Benan","family":"Kilbas","sequence":"first","affiliation":[{"name":"Moltek A.S. Gebze Organize Sanayi, 41400 Gebze, Kocaeli, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurtulus","family":"Eryilmaz","sequence":"additional","affiliation":[{"name":"Moltek A.S. Gebze Organize Sanayi, 41400 Gebze, Kocaeli, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"4918","DOI":"10.1039\/b704726f","volume":"43","author":"Brechbiel M.W.","year":"2007","unstructured":"Brechbiel M.W.; Targeted alpha-therapy: past, present, future? Dalton Trans 2007,43(43),4918-4928","journal-title":"Dalton Trans"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"4314","DOI":"10.3390\/molecules24234314","volume":"24","author":"Tafreshi N.K.","year":"2019","unstructured":"Tafreshi N.K.; Doligalski M.L.; Tichacek C.J.; Pandya D.N.; Budzevich M.M.; El-Haddad G.; Khushalani N.I.; Moros E.G.; McLaughlin M.L.; Wadas T.J.; Morse D.L.; Development of targeted alpha particle therapy for solid tumors. Molecules 2019,24(23),4314","journal-title":"Molecules"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"324","DOI":"10.3389\/fonc.2013.00324","volume":"3","author":"Elgqvist J.","year":"2014","unstructured":"Elgqvist J.; Frost S.; Pouget J.P.; Albertsson P.; The potential and hurdles of targeted alpha therapy - clinical trials and beyond. Front Oncol 2014,3,324","journal-title":"Front Oncol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"311","DOI":"10.2967\/jnumed.108.058651","volume":"51","author":"Sgouros G.","year":"2010","unstructured":"Sgouros G.; Roeske J.C.; McDevitt M.R.; Palm S.; Allen B.J.; Fisher D.R.; Brill A.B.; Song H.; Howell R.W.; Akabani G.; Bolch W.E.; Brill A.B.; Fisher D.R.; Howell R.W.; Meredith R.F.; Sgouros G.; Wessels B.W.; Zanzonico P.B.; MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy. J Nucl Med SNM MIRD Committee2010,51(2),311-328","journal-title":"J Nucl Med"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1001\/jamaoncol.2018.4044","volume":"4","author":"Parker C.","year":"2018","unstructured":"Parker C.; Lewington V.; Shore N.; Kratochwil C.; Levy M.; Lind\u00e9n O.; Noordzij W.; Park J.; Saad F.; Targeted alpha therapy, an emergingclass of cancer agents a review. JAMA Oncol Targeted Alpha Therapy Working Group2018,4(12),1765-1772","journal-title":"JAMA Oncol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1053\/j.semnuclmed.2019.02.003","volume":"49","author":"Kratochwil C.","year":"2019","unstructured":"Kratochwil C.; Haberkorn U.; Giesel F.L.; Radionuclide therapy of metastatic prostate cancer. Semin Nucl Med 2019,49(4),313-325","journal-title":"Semin Nucl Med"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"4451","DOI":"10.1158\/1078-0432.CCR-04-2244","volume":"11","author":"Nilsson S.","year":"2005","unstructured":"Nilsson S.; Larsen R.H.; Foss\u00e5 S.D.; Balteskard L.; Borch K.W.; Westlin J.E.; Salberg G.; Bruland O.S.; First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res 2005,11(12),4451-4459","journal-title":"Clin Cancer Res"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1093\/annonc\/mdw065","volume":"27","author":"Nilsson S.","year":"2016","unstructured":"Nilsson S.; Cislo P.; Sartor O.; Vogelzang N.J.; Coleman R.E.; O\u2019Sullivan J.M.; Reuning-Scherer J.; Shan M.; Zhan L.; Parker C.; Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study. Ann Oncol 2016,27(5),868-874","journal-title":"Ann Oncol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.2967\/jnumed.118.220384","volume":"60","author":"Hallqvist A.","year":"2019","unstructured":"Hallqvist A.; Bergmark K.; B\u00e4ck T.; Andersson H.; Dahm-K\u00e4hler P.; Johansson M.; Lindegren S.; Jensen H.; Jacobsson L.; Hultborn R.; Palm S.; Albertsson P.; Intraperitoneal \u03b1-Emitting Radioimmunotherapy with At in Relapsed Ovarian Cancer: Long-Term Follow-up with Individual Absorbed Dose Estimations. J Nucl Med 2019,60(8),1073-1079","journal-title":"J Nucl Med"},{"key":"ref=10","first-page":"559","volume":"60","author":"Delpassand E.","year":"2019","unstructured":"Delpassand E.; Tworowska I.; Shanoon F.; Nunez R.; Flores L.; Muzammil A.; Stallons T.; Saidi A.; Torgue J.; First clinical experience using targeted alpha- emitter therapy with Pb-212- DOTAMTATE (AlphaMedix TM) in patients with SSTR(+) neuroendocrine tumors. J Nucl Med 2019,60,559","journal-title":"J Nucl Med"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1007\/s00259-014-2857-9","volume":"41","author":"Kratochwil C.","year":"2014","unstructured":"Kratochwil C.; Giesel F.L.; Bruchertseifer F.; Mier W.; Apostolidis C.; Boll R.; Murphy K.; Haberkorn U.; Morgenstern A.; \u00b2\u00b9\u00b3Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience. Eur J Nucl Med Mol Imaging 2014,41(11),2106-2119","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.2967\/jnumed.116.178673","volume":"57","author":"Kratochwil C.","year":"2016","unstructured":"Kratochwil C.; Bruchertseifer F.; Giesel F.L.; Weis M.; Verburg F.A.; Mottaghy F.; Kopka K.; Apostolidis C.; Haberkorn U.; Morgenstern A.; 225Ac-PSMA-617 for PSMA-Targeted \u03b1-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer. J Nucl Med 2016,57(12),1941-1944","journal-title":"J Nucl Med"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0969-8051(99)00024-4","volume":"26","author":"Davis I. A.","year":"1999","unstructured":"Davis I. A.; Glowienka K. A.; Boll R. A.; Deal K. A.; Brechbiel M. W.; Stabin M.; Bochsler P. N.; Mirzadeh S.; Kennel S. J.; Comparison of 225actinium chelates: Tissue distribution and radiotoxicity. Nucl Med Bio 1999,26,581-589","journal-title":"Nucl Med Bio"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"200","DOI":"10.2174\/1874471011666180502104524","volume":"11","author":"Morgenstern A.","year":"2018","unstructured":"Morgenstern A.; Apostolidis C.; Kratochwil C.; Sathekge M.; Krolicki L.; Bruchertseifer F.; An Overview of Targeted Alpha Therapy with Actinium and Bismuth. Curr Radiopharm 2018,11(3),200-208","journal-title":"Curr Radiopharm"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1007\/s00259-020-04725-x","volume":"47","author":"Ocak M.","year":"2020","unstructured":"Ocak M.; Toklu T.; Demirci E.; Sel\u00e7uk N.; Kabasakal L.; Post-therapy imaging of Ac-DOTATATE treatment in a patient with recurrent neuroendocrine tumor. Eur J Nucl Med Mol Imaging 2020,47(11),2711-2712","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1007\/s00259-019-04567-2","volume":"47","author":"Ballal S.","year":"2020","unstructured":"Ballal S.; Yadav M.P.; Bal C.; Sahoo R.K.; Tripathi M.; Broadening horizons with Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to Lu-DOTATATE PRRT: first clinical experience on the efficacy and safety. Eur J Nucl Med Mol Imaging 2020,47(4),934-946","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S0969-8051(97)80001-7","volume":"24","author":"Beyer G.J.","year":"1997","unstructured":"Beyer G.J.; Offord R.; K\u00fcnzi G.; Aleksandrova Y.; Ravn U.; Jahn S.; Barker J.; Tengblad O.; Lindroos M.; The influence of EDTMP-concentration on the biodistribution of radio-lanthanides and 225-Ac in tumor-bearing mice. Nucl Med Biol The ISOLDE Collaboration1997,24(5),367-372","journal-title":"Nucl Med Biol"},{"key":"ref=18","author":"Kelly M.J.","year":"2020","unstructured":"Kelly M.J.; Coarasa A.A.; Sweeney E.; Babich W.J.;  A Consensus Time for Performing Quality Control of 225Ac-Labeled Radiopharmaceuticals 2020","journal-title":"A Consensus Time for Performing Quality Control of 225Ac-Labeled Radiopharmaceuticals"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"11671","DOI":"10.1038\/s41598-019-48298-8","volume":"9","author":"Kruijff R.M.","year":"2019","unstructured":"Kruijff R.M.; Raav\u00e9 R.; Kip A.; Molkenboer-Kuenen J.; Morgenstern A.; Bruchertseifer F.; Heskamp S.; Denkova A.G.; The in vivo fate of Ac daughter nuclides using polymersomes as a model carrier. Sci Rep 2019,9(1),11671-11684","journal-title":"Sci Rep"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1007\/s00259-002-1054-4","volume":"30","author":"Breeman W.A.","year":"2003","unstructured":"Breeman W.A.; van der Wansem K.; Bernard B.F.; van Gameren A.; Erion J.L.; Visser T.J.; Krenning E.P.; de Jong M.; The addition of DTPA to [177Lu-DOTA0,Tyr]octreotate prior to administration reduces rat skeleton uptake of radioactivity. Eur J Nucl Med Mol Imaging 2003,30(2),312-315","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3390\/ph10020045","volume":"10","author":"Pfannkuchen N.","year":"2017","unstructured":"Pfannkuchen N.; Meckel M.; Bergmann R.; Bachmann M.; Bal C.; Sathekge M.; Mohnike W.; Baum R.P.; R\u00f6sch F.; Novel Radiolabeled Bisphosphonates for PET Diagnosis and Endoradiotherapy of Bone Metastases. Pharmaceuticals (Basel) 2017,10(2),45-57","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1159\/000337634","volume":"7","author":"Fischer M.","year":"2012","unstructured":"Fischer M.; Kampen W.U.; Radionuclide Therapy of Bone Metastases. Breast Care (Basel) 2012,7(2),100-107","journal-title":"Breast Care (Basel)"}],"container-title":["Current Radiopharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1874471014666210528123936","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/193656\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1874471014666210528123936","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T16:27:46Z","timestamp":1662049666000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/193656\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1874471014666210528123936","relation":{},"ISSN":["1874-4710"],"issn-type":[{"value":"1874-4710","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-10-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-19","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}